

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kumar Neil</u>			2. Issuer Name and Ticker or Trading Symbol <u>BridgeBio Pharma, Inc. [BBIO]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CEO and President		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>11/16/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
<u>PALO ALTO</u>	<u>CA</u>	<u>94304</u>						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/16/2023		M		102,249	A	(1)	4,915,446	D	
Common Stock	11/16/2023		F		50,697 ⁽²⁾	D	\$28.86	4,864,749	D	
Common Stock	11/17/2023		S ⁽³⁾		51,352	D	\$29.0958 ⁽⁴⁾	4,813,397	D	
Common Stock	11/17/2023		S ⁽³⁾		200	D	\$29.55	4,813,197	D	
Common Stock								1,012,722	I	See Footnote ⁽⁵⁾
Common Stock								995,686	I	See Footnote ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(1)	11/16/2023		M		5,129		(7)	(7)	Common Stock	5,129	\$0.00	10,259	D	
Restricted Stock Units	(1)	11/16/2023		M		2,394		(8)	(8)	Common Stock	2,394	\$0.00	11,971	D	
Restricted Stock Units	(1)	11/16/2023		M		61,182		(9)	(9)	Common Stock	61,182	\$0.00	61,182	D	
Restricted Stock Units	(1)	11/16/2023		M		33,544		(10)	(10)	Common Stock	33,544	\$0.00	436,072	D	

Explanation of Responses:

- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 102,249 shares of Common Stock underlying the Reporting Person's RSUs.
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2022.
- Represents the weighted average sale price of the shares sold from \$28.55 to \$29.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
- The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to

the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

10. The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Remarks:

/s/ Brian C. Stephenson,
Attorney-in-Fact

11/20/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.